Compare Stocks: KYNB, OKUR, ATRA, and EQ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$9.34 +0.3%	$9.17	$3.92 ▼ $19.15	$93.77M	0.21	608,011 shs	5,248 shs
EQ Equillium	$1.31 -0.5%	$2.00	$0.76 ▼ $3.54	$83.64M	1.93	751,736 shs	397,688 shs
KYNB Kyntra Bio	$5.93 +1.1%	$7.26	$5.62 ▼ $11.65	$24.40M	1.05	26,199 shs	15,928 shs
OKUR OnKure Therapeutics	$2.34 -0.5%	$3.32	$2.13 ▼ $5.38	$94.13M	0.12	260,882 shs	2,607 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-0.75%	-4.51%	-0.75%	+8.89%	-38.10%
EQ Equillium	-12.00%	-7.04%	-37.44%	-49.62%	+3.13%
KYNB Kyntra Bio	-4.08%	-1.51%	-26.35%	-18.59%	+586,999,900.00%
OKUR OnKure Therapeutics	-2.89%	-4.47%	-24.19%	-44.18%	-18.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$9.34 +0.3%	$9.17	$3.92 ▼ $19.15	$93.77M	0.21	608,011 shs	5,248 shs
EQ Equillium	$1.31 -0.5%	$2.00	$0.76 ▼ $3.54	$83.64M	1.93	751,736 shs	397,688 shs
KYNB Kyntra Bio	$5.93 +1.1%	$7.26	$5.62 ▼ $11.65	$24.40M	1.05	26,199 shs	15,928 shs
OKUR OnKure Therapeutics	$2.34 -0.5%	$3.32	$2.13 ▼ $5.38	$94.13M	0.12	260,882 shs	2,607 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-0.75%	-4.51%	-0.75%	+8.89%	-38.10%
EQ Equillium	-12.00%	-7.04%	-37.44%	-49.62%	+3.13%
KYNB Kyntra Bio	-4.08%	-1.51%	-26.35%	-18.59%	+586,999,900.00%
OKUR OnKure Therapeutics	-2.89%	-4.47%	-24.19%	-44.18%	-18.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.50	Moderate Buy	$9.50	2.04% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	473.59% Upside
KYNB Kyntra Bio	2.43	Hold	$36.80	526.92% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	644.68% Upside

Current Analyst Ratings Breakdown

Latest KYNB, OKUR, ATRA, and EQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	KYNB Kyntra Bio	Maxim Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$35.00
10/12/2026	EQ Equillium	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$6.00
10/12/2026	KYNB Kyntra Bio	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/9/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)
10/9/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/21/2026	EQ Equillium	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$41.00
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$41.00
9/4/2026	EQ Equillium	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$12.00
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$43.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$120.77M	0.77	$4.82 per share	1.93	($5.34) per share	-1.74
EQ Equillium	$41.10M	2.04	N/A	N/A	$0.47 per share	2.81
KYNB Kyntra Bio	$6.44M	3.69	N/A	N/A	($4.20) per share	-1.40
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	6.75	N/A	-269.42%	N/A	-73.01%	10/29/2026 (Estimated)
EQ Equillium	-$22.40M	-$0.20	N/A	N/A	N/A	N/A	-41.15%	-38.29%	11/12/2026 (Estimated)
KYNB Kyntra Bio	$183.45M	$45.30	0.13	N/A	N/A	2,199.13%	N/A	-47.27%	N/A
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)

Latest KYNB, OKUR, ATRA, and EQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ATRA Atara Biotherapeutics	-$0.1328	N/A	N/A	N/A	$0.80 million	N/A
11/5/2026	Q3 2026	OKUR OnKure Therapeutics	-$0.36	N/A	N/A	N/A	$0.17 million	N/A
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.98	1.98
EQ Equillium	N/A	23.40	23.40
KYNB Kyntra Bio	N/A	2.69	2.59
OKUR OnKure Therapeutics	N/A	26.75	26.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
EQ Equillium	27.05%
KYNB Kyntra Bio	72.71%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
EQ Equillium	17.84%
KYNB Kyntra Bio	4.15%
OKUR OnKure Therapeutics	2.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	10	10.04 million	5.90 million	No Data
EQ Equillium	14	63.41 million	52.10 million	Not Optionable
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
OKUR OnKure Therapeutics	45	40.40 million	39.52 million	N/A

KYNB, OKUR, ATRA, and EQ Headlines

Recent News About These Companies

OnKure Therapeutics (NASDAQ:OKUR) Stock Falls 4.8% - Here's What Happened

September 28, 2026 | marketbeat.com

Onkure Therapeutics Inc (OKUR)

September 25, 2026 | investing.com

OnKure Therapeutics, Inc. Class A Common Stock

September 24, 2026 | fxempire.comF

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

August 31, 2026 | globenewswire.com

OnKure Therapeutics Inc. - Ordinary Shares - Class A

August 19, 2026 | money.usnews.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)

August 6, 2026 | theglobeandmail.com

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 4, 2026 | globenewswire.com

OnKure Therapeutics Stock Short Interest Report | NASDAQ:OKUR | Benzinga

July 14, 2026 | benzinga.com

Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.04%

July 10, 2026 | aaii.comA

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

July 2, 2026 | globenewswire.com

OnKure Therapeutics, Inc. Class A

June 9, 2026 | edition.cnn.com

OnKure Shareholders Approve Amended 2024 Equity Incentive Plan

June 4, 2026 | tipranks.com

Onkure Therapeutics (OKUR) Stock Forecast & Price Target

May 22, 2026 | investing.com

OnKure Therapeutics (OKUR) Receives a Buy from Oppenheimer

May 8, 2026 | theglobeandmail.com

OnKure Therapeutics war chest nears $200M following spring stock sale

May 6, 2026 | bizwest.comB

OnKure Therapeutics Reports First Quarter 2026 Financial Results

May 5, 2026 | globenewswire.com

OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60

April 28, 2026 | msn.com

OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading

April 26, 2026 | theglobeandmail.com

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...

March 27, 2026 | finance.yahoo.com

OnKure to sell $150M in stock to fund drug development

March 27, 2026 | bizwest.comB

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

March 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KYNB, OKUR, ATRA, and EQ Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$9.34 +0.03 (+0.32%)

As of 09:09 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Equillium NASDAQ:EQ

$1.31 -0.01 (-0.45%)

As of 09:39 AM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Kyntra Bio NASDAQ:KYNB

$5.93 +0.06 (+1.06%)

As of 09:39 AM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

OnKure Therapeutics NASDAQ:OKUR

$2.34 -0.01 (-0.51%)

As of 09:40 AM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYNB, OKUR, ATRA, and EQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYNB, OKUR, ATRA, and EQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYNB, OKUR, ATRA, and EQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYNB, OKUR, ATRA, and EQ Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Equillium NASDAQ:EQ

Kyntra Bio NASDAQ:KYNB

OnKure Therapeutics NASDAQ:OKUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYNB, OKUR, ATRA, and EQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYNB, OKUR, ATRA, and EQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYNB, OKUR, ATRA, and EQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYNB, OKUR, ATRA, and EQ Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Equillium NASDAQ:EQ

Kyntra Bio NASDAQ:KYNB

OnKure Therapeutics NASDAQ:OKUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools